ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Microbiome

Genentech and Microbiotica in IBD pact

by Lisa M. Jarvis
June 11, 2018 | APPEARED IN VOLUME 96, ISSUE 24

 

Genentech has teamed with Microbiotica to develop tests, drug targets, and treatments for inflammatory bowel disease. Financial specifics of the deal were not disclosed, but Microbiotica could earn up to $534 million in the collaboration. Microbiotica was spun out of the Wellcome Sanger Institute in 2016 with expertise in unraveling host-microbiome interactions. It will analyze samples from patients in clinical trials of Genentech’s IBD drugs to find biomarkers that indicate a drug is working, identify novel IBD drug targets, and develop bacteria-based therapeutics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment